A number of firms have modified their ratings and price targets on shares of Flexion Therapeutics (NASDAQ: FLXN) recently:

  • 10/18/2017 – Flexion Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 10/17/2017 – Flexion Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “
  • 10/10/2017 – Flexion Therapeutics had its price target raised by analysts at Janney Montgomery Scott to $570.00. They now have a “fair value” rating on the stock.
  • 10/10/2017 – Flexion Therapeutics had its “buy” rating reaffirmed by analysts at Laidlaw. They now have a $38.00 price target on the stock, up previously from $35.00.
  • 10/10/2017 – Flexion Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “
  • 10/9/2017 – Flexion Therapeutics had its price target raised by analysts at Needham & Company LLC from $36.00 to $42.00. They now have a “buy” rating on the stock.
  • 10/9/2017 – Flexion Therapeutics had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $37.00 price target on the stock, up previously from $35.00.
  • 10/6/2017 – Flexion Therapeutics was given a new $39.00 price target on by analysts at Wells Fargo & Company. They now have a “buy” rating on the stock.
  • 10/4/2017 – Flexion Therapeutics had its “buy” rating reaffirmed by analysts at Northland Securities. They now have a $40.00 price target on the stock.
  • 9/17/2017 – Flexion Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
  • 9/11/2017 – Flexion Therapeutics was given a new $44.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 9/1/2017 – Flexion Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/28/2017 – Flexion Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

Shares of Flexion Therapeutics, Inc. (FLXN) opened at 21.98 on Tuesday. The firm’s market cap is $701.27 million. Flexion Therapeutics, Inc. has a 12-month low of $15.93 and a 12-month high of $32.25. The company has a 50-day moving average of $25.03 and a 200 day moving average of $22.44.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11). Equities analysts predict that Flexion Therapeutics, Inc. will post ($3.80) EPS for the current year.

In other news, insider Yamo Deniz purchased 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were acquired at an average price of $24.15 per share, for a total transaction of $72,450.00. Following the completion of the acquisition, the insider now directly owns 5,000 shares in the company, valued at $120,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders purchased 5,375 shares of company stock worth $131,575. 15.98% of the stock is owned by company insiders.

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.